<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guttate psoriasis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guttate psoriasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Guttate psoriasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie Mehlis, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1391875244"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Psoriasis is a common skin disorder characterized by the development of inflammatory plaques on the skin. The spectrum of clinical manifestations of psoriasis is wide and includes chronic plaque, guttate, inverse, erythrodermic, pustular, and nail variants of the disease. (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Patients with guttate psoriasis typically present with the acute onset of numerous small, inflammatory, scaly plaques on the trunk and extremities  (<a class="graphic graphic_picture graphicRef55141 graphicRef64836" href="/d/graphic/55141.html" rel="external">picture 1A-B</a>). Guttate psoriasis is most common among children and young adults, and a preceding history of streptococcal infection is often present.</p><p>The epidemiology, clinical manifestations, and treatment of guttate psoriasis will be reviewed here. Other manifestations of psoriasis are discussed separately. (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p class="headingAnchor" id="H1391875258"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Psoriasis occurs in 0.6 to 4.8 percent of the general population [<a href="#rid1">1</a>], with chronic plaque psoriasis as the most common clinical presentation. Estimates of the proportion of patients with psoriasis who develop guttate disease vary widely; many studies cite a prevalence of less than 30 percent among patients with psoriasis [<a href="#rid2">2-6</a>].</p><p>Guttate psoriasis is most frequently diagnosed in children and young adults under the age of 30; however, older individuals may also be affected [<a href="#rid7">7-9</a>]. As an example, in a Spanish study that compared 1092 patients in whom psoriasis began between the ages of 0 and 30 years with 662 patients with disease onset later in life, patients in the younger-onset group were significantly more likely to have the guttate variant (15 versus 7 percent) [<a href="#rid8">8</a>].</p><p>A sex predilection for guttate psoriasis has not been established. Both males and females may develop this disease.</p><p class="headingAnchor" id="H2500968"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Genetic and environmental factors likely contribute to the development of guttate psoriasis. The class I human leukocyte antigen HLA-Cw6 (in particular, the HLA Cw*0602 allele) and beta-hemolytic streptococci are the primary factors linked to the development of this disease.</p><p class="headingAnchor" id="H2500143"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The HLA-Cw*0602 allele is strongly associated with psoriasis [<a href="#rid10">10</a>]. In a meta-analysis of 18 studies with approximately 3400 patients with psoriasis and 3300 healthy controls, participants who were positive for HLA-Cw*0602 were more than four times more likely to have psoriasis than participants who were negative for the allele (odds ratio 4.55, 95% CI 3.65-5.67) [<a href="#rid11">11</a>].</p><p>The association between psoriasis and the HLA-Cw*0602 allele appears to be particularly strong among patients with guttate psoriasis [<a href="#rid5">5,12-16</a>]. Examples of studies in support of an association include:</p><p class="bulletIndent1"><span class="glyph">●</span>In an Icelandic study that evaluated the correlation between HLA-Cw6 status and disease characteristics in patients with familial psoriasis, 31 of 33 patients (94 percent) whose symptoms began as an acute guttate eruption demonstrated HLA-Cw6 positivity [<a href="#rid16">16</a>]. An extension of this study that included patients without a family history of psoriasis (n = 1019) found the prevalence of guttate disease was significantly greater among HLA-Cw*0602 positive patients than among HLA-Cw*0602 negative patients (11 versus 3 percent) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Swedish case-control study, 56 of 77 patients with guttate psoriasis (73 percent) were positive for the HLA-Cw*0602 allele compared with 39 or 371 controls (11 percent) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a United Kingdom study of 29 patients with guttate psoriasis and 604 controls, the HLA-Cw*0602 allele was detected in all patients with guttate psoriasis compared with only 20 percent of controls [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Chinese study found that HLA-Cw*0602 was strongly associated with guttate psoriasis; the guttate presentation accounted for 21 percent of psoriasis cases in HLA-Cw*0602 positive patients with psoriasis and 9 percent of psoriasis cases in HLA-Cw*0602 negative patients with psoriasis [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H2500010"><span class="h2">Streptococcal infection</span><span class="headingEndMark"> — </span>Streptococcal infection often precedes the onset of guttate psoriasis [<a href="#rid7">7,17-21</a>]. A link between these entities is supported by studies that have documented a relationship between new-onset guttate psoriasis and acute streptococcal pharyngitis in 56 to 97 percent of patients [<a href="#rid18">18</a>]. In addition, perianal streptococcal infection has preceded guttate psoriasis in children [<a href="#rid22">22,23</a>]. The cutaneous manifestations of guttate psoriasis typically develop two to three weeks after an associated streptococcal infection [<a href="#rid7">7</a>].</p><p>New-onset guttate psoriasis may be more likely to be associated with streptococcal infections than guttate psoriasis that develops in patients with pre-existing chronic plaque psoriasis. In a prospective study, 19 of 33 patients (58 percent) with acute guttate psoriasis versus 7 of 27 patients (26 percent) with guttate exacerbations of chronic psoriasis had serologic evidence for recent streptococcal infection [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2500017"><span class="h2">Other infections</span><span class="headingEndMark"> — </span>Case reports have documented the development of guttate psoriasis following varicella [<a href="#rid24">24,25</a>] and <em>Pityrosporum</em> folliculitis [<a href="#rid26">26,27</a>]. A Koebner phenomenon, in which wound healing triggers hyperproliferative changes in the skin, may be a factor in these cases. Cases of guttate psoriasis following coronavirus disease 2019 (COVID-19) infection or vaccination have also been reported [<a href="#rid28">28-31</a>]. Guttate psoriasis has also developed in the site of a tattoo, a finding consistent with the theory of Koebnerization [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H2500846"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Guttate psoriasis has been reported after treatment with tumor necrosis factor (TNF)-alpha inhibitors in case reports and case series [<a href="#rid33">33-37</a>]. The reason for this paradoxical observation is unclear but may involve disruption of the cytokine milieu, leading to unopposed interferon production [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1391875265"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathophysiology of guttate psoriasis is not well understood. Interplay between genetic and environmental factors leading to an aberrant immune response in the skin may contribute to disease development.</p><p>As noted above, strong associations between guttate psoriasis, streptococcal infection, and HLA-Cw*0602 positivity have been detected in patients with guttate psoriasis (see <a class="local">'Risk factors'</a> above). Examples of proposed mechanisms for the relationship between guttate psoriasis and streptococcal infection include [<a href="#rid38">38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cross-reactivity between streptococcal M-proteins (the major pathogenic antigens on beta-hemolytic streptococci) presented to immune cells in the tonsils and structurally similar type I keratins in the epidermis (K16 and K17) trigger a T cell-mediated autoimmune response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Streptococcal superantigens in the tonsils may augment the expression of the skin-homing cutaneous lymphocyte antigen (CLA) on effector T cells, contributing to the migration of T cells into the skin; CD4+ cells migrate into the dermis, and CD8+ cells migrate into the epidermis. A study that found identical T cell receptor gene rearrangement in tonsils and psoriatic skin in patients with streptococcal-induced psoriasis supports direct migration of CLA+ cells in the tonsils to the skin [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An innate immune-mediated inflammatory response occurs as a consequence of the binding of peptidoglycan or other streptococcal antigens to cell receptors.</p><p></p><p>The observed association between guttate psoriasis and HLA-Cw*0602 may be related to interactions between streptococci and this molecule [<a href="#rid12">12</a>]. In an in vitro study, homologous peptides from K17 and streptococcal M-protein that were predicted to bind to HLA-Cw6 were better able to stimulate interferon (IFN)-gamma production in T cells (mostly CD8+ T cells that also demonstrated CLA) from patients with psoriasis than T cells obtained from patients without psoriasis [<a href="#rid40">40</a>]. Moreover, the greatest responses were detected in T cells derived from HLA-Cw*0602 positive patients with psoriasis.</p><p>Another ex vivo study supports a role for interactions between streptococci and HLA-Cw*0602. Coculture of CLA+ T cells and autologous epidermal cells from patients with guttate psoriasis in the presence of <em>Streptococcus pyogenes</em> led to a higher Th17 response (higher production of interleukin [IL]-17A and IL-17F than IFN-gamma) with cells from carriers of HLA-Cw*0602 who had psoriasis flares associated with pharyngitis than with cells from HLA-Cw*0602 positive or negative patients who did not have flares associated with pharyngitis [<a href="#rid41">41</a>]. Th17 cells play an important role in the pathogenesis of psoriasis. (See  <a class="medical medical_review" href="/d/html/15277.html" rel="external">"Pathophysiology of plaque psoriasis", section on 'T helper type 17 cells'</a>.)</p><p>Clinical evidence of a relationship between HLA-Cw*0602 status, guttate psoriasis, and streptococcal infection was detected in a study of 439 patients with plaque psoriasis, 143 patients with guttate psoriasis, and 454 healthy controls. Patients with guttate psoriasis who were positive for HLA-Cw*0602 were more likely to have a positive streptococcal throat swab than patients who were HLA-Cw*0602 negative (odds ratio 3.5, 95% CI 1.5-8.7) [<a href="#rid13">13</a>]. A difference in throat swab positivity rates based upon HLA-Cw*0602 status was not detected among the healthy controls.</p><p class="headingAnchor" id="H2177455101"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Guttate psoriasis is characterized by the acute eruption of numerous small, erythematous papules and plaques. The term "guttate" is utilized to refer to the discrete, drop-like appearance of skin lesions. The eruption may present as a new-onset disorder in patients without a history of psoriasis or as a new presentation of psoriasis in patients with pre-existing chronic plaque-type disease [<a href="#rid19">19</a>].</p><p>Individual lesions usually measure between 2 and 15 mm in diameter and demonstrate fine, overlying scale  (<a class="graphic graphic_picture graphicRef55141 graphicRef64836" href="/d/graphic/55141.html" rel="external">picture 1A-B</a>). The trunk and proximal extremities are classically involved, although lesions may also occur in other sites, such as the scalp, hands, feet, and nails [<a href="#rid7">7</a>]. Pruritus and postinflammatory hyperpigmentation may occur.</p><p class="headingAnchor" id="H1391875279"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Clinical examination is usually sufficient for the diagnosis of guttate psoriasis. A skin biopsy can be used to support the diagnosis in difficult cases.</p><p class="headingAnchor" id="H2500097"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>The histopathologic findings of guttate psoriasis vary with the age of the lesion [<a href="#rid42">42</a>]. The findings in early lesions may be nondiagnostic, demonstrating mild acanthosis, papillary dermal edema, capillary dilatation, and a sparse lymphocyte-predominant dermal infiltrate.</p><p>Mature lesions more closely resemble the pathology findings in chronic plaque psoriasis. Such lesions have parakeratosis alternating with hyperkeratosis, epidermal acanthosis, rete ridge elongation, and collections of neutrophils in the epidermis that are also known as Munro microabscesses. Dermal findings include dilated, tortuous vessels and a superficial perivascular infiltrate containing lymphocytes, neutrophils, and macrophages.</p><p class="headingAnchor" id="H2500854"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>No serologic tests provide a definitive diagnosis of guttate psoriasis. Routine assessment for evidence of a streptococcal infection in patients without infectious symptoms is controversial because a benefit of antibacterial therapy in guttate psoriasis is unproven [<a href="#rid43">43</a>]. In our opinion, laboratory testing is not necessary in patients without active signs or symptoms of streptococcal infection.</p><p>Patients who present with symptoms suggestive of streptococcal pharyngitis or other forms of streptococcal infection should be evaluated with appropriate laboratory studies to facilitate the identification and treatment of these conditions. Symptoms of streptococcal pharyngitis include sore throat, tonsillar exudate, tender cervical adenitis, and fever. (See  <a class="medical medical_review" href="/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults"</a> and  <a class="medical medical_review" href="/d/html/5971.html" rel="external">"Group A streptococcal tonsillopharyngitis in children and adolescents: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2500104"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Multiple disorders may present with clinical features that resemble guttate psoriasis. In most cases, the clinical history and physical examination are sufficient for differentiating guttate psoriasis from other diseases. Occasionally, laboratory studies are needed to assist with diagnosis.</p><p>Examples of disorders in the differential diagnosis of guttate psoriasis include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pityriasis rosea </strong>– Pityriasis rosea presents with the acute eruption of multiple oval inflammatory plaques  (<a class="graphic graphic_picture graphicRef98333 graphicRef57568 graphicRef87126 graphicRef98334" href="/d/graphic/98333.html" rel="external">picture 2A-D</a>). Like guttate psoriasis, the trunk and proximal extremities are prominent sites of involvement. The classic features of a "Christmas tree" pattern distribution and collarette of scale can be useful clues for the identification of pityriasis rosea. At least 50 percent also develop a large, oval plaque (also known as a herald plaque) prior to the development of the widespread eruption. (See  <a class="medical medical_review" href="/d/html/5665.html" rel="external">"Pityriasis rosea"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea corporis </strong>– Extensive tinea corporis may present with numerous annular plaques on the skin  (<a class="graphic graphic_picture graphicRef55949 graphicRef103984" href="/d/graphic/55949.html" rel="external">picture 3A-B</a>). Peripheral scale and central clearing are commonly seen. A potassium hydroxide (KOH) preparation is useful for diagnosis. (See  <a class="medical medical_review" href="/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea corporis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary syphilis </strong>– Secondary syphilis is characterized by the development of erythematous to brown macules, papules, or small plaques in a generalized distribution  (<a class="graphic graphic_picture graphicRef60313 graphicRef65500 graphicRef122598" href="/d/graphic/60313.html" rel="external">picture 4A-C</a>). Involvement of the palms and soles suggests the possibility of this diagnosis. Serologic findings and histopathologic examination are also useful for diagnosis. (See  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pityriasis lichenoides chronica </strong>– Pityriasis lichenoides chronica is an uncommon skin disorder that presents with recurrent crops of erythematous to brown papules on the trunk and proximal extremities  (<a class="graphic graphic_picture graphicRef71210 graphicRef89407" href="/d/graphic/71210.html" rel="external">picture 5A-B</a>). Lesions often demonstrate an adherent (micaceous) scale. Pruritus may or may not be present. The disorder is most common in children and young adults. (See  <a class="medical medical_review" href="/d/html/15287.html" rel="external">"Pityriasis lichenoides chronica"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small plaque parapsoriasis </strong>– Small plaque parapsoriasis is a rare condition in which multiple small, oval patches with fine scale develop on the trunk and proximal extremities  (<a class="graphic graphic_picture graphicRef87290 graphicRef87291" href="/d/graphic/87290.html" rel="external">picture 6A-B</a>). The eruption may be asymptomatic or mildly pruritic. (See  <a class="medical medical_review" href="/d/html/15284.html" rel="external">"Parapsoriasis (small plaque and large plaque parapsoriasis)", section on 'Small plaque parapsoriasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nummular dermatitis </strong>– Nummular dermatitis (also known as nummular eczema) may present with single or multiple oval, inflammatory plaques  (<a class="graphic graphic_picture graphicRef58067 graphicRef116644 graphicRef96164" href="/d/graphic/58067.html" rel="external">picture 7A-C</a>). Pruritus is typically prominent. Serous drainage may be present. (See  <a class="medical medical_review" href="/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)", section on 'Nummular eczema'</a>.)</p><p></p><p>Although the cutaneous features of viral exanthems and maculopapular drug eruptions tend to differ from guttate psoriasis, the clinical scenarios in which guttate psoriasis develops (a new, widespread skin eruption in a patient with a recent history of upper respiratory symptoms or a history of streptococcal pharyngitis treated with antibiotics) may lead to consideration of these diagnoses  (<a class="graphic graphic_picture graphicRef83682 graphicRef54205" href="/d/graphic/83682.html" rel="external">picture 8A-B</a>). Recognition of the well-defined plaques with adherent scale that are characteristic of guttate psoriasis is useful for distinguishing this diagnosis.</p><p class="headingAnchor" id="H2501744"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>Guttate psoriasis may spontaneously remit, typically over the course of several weeks to several months, may intermittently recur, or may persist and progress into chronic plaque psoriasis [<a href="#rid7">7,21,44,45</a>]. Few data are available on the prognosis of guttate psoriasis, precluding reliable predictions about the disease course in individual patients. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>The Stockholm Psoriasis Cohort study (n = 721) evaluated long-term outcomes in adolescents and adults with recent-onset psoriasis [<a href="#rid46">46</a>]. Of the 116 patients with guttate psoriasis who were re-examined after 10 years, 48 percent had minimal disease activity without treatment (as compared with 20 percent of 389 patients with plaque-onset psoriasis re-examined after 10 years).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study assessed 36 patients with childhood or adult-onset guttate psoriasis who lacked a preceding history of psoriasis [<a href="#rid7">7</a>]. Complete remission lasting for at least one year occurred in 22 patients (61 percent) with a mean time to disease clearance of 3.9±2.4 months, and the remaining 14 patients progressed to chronic plaque-type disease. Of note, three patients in the remission group had recurrence after one year. A wide variety of treatments for guttate psoriasis were utilized in the patients in this study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study assessed 79 patients with guttate psoriasis and no prior history of psoriasis who were followed for a least one year (median follow-up period of five years). In the study, 20 patients (25 percent) progressed to plaque psoriasis [<a href="#rid47">47</a>]. The results of a molecular probe for streptococci appeared to correlate with risk for plaque psoriasis; however, additional data are necessary to confirm this finding. Among the 31 patients who had the molecular probe performed, none of the five patients who developed plaque psoriasis had a positive molecular probe for streptococci compared with 16 of 26 patients (62 percent) who did not develop plaque psoriasis. A similar correlation with antistreptolysin O titers was not detected. </p><p></p><p>Further study is necessary to determine whether a preceding history of guttate psoriasis is associated with greater severity of chronic plaque-type disease [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1391875286"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatments used for guttate psoriasis overlap with those utilized for chronic plaque psoriasis. Although many treatments for chronic plaque psoriasis have been extensively studied, investigations focused specifically on treatment results in guttate psoriasis are limited [<a href="#rid48">48-50</a>]. (See  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p>Given the possibility for spontaneous remission of guttate psoriasis within several weeks or several months, foregoing treatment is an option for patients who prefer to avoid therapy. However, since the time required for disease remittance is unpredictable and persistence of psoriasis is not uncommon, in our experience, many patients elect to proceed with treatment. (See <a class="local">'Clinical course'</a> above.)</p><p>First-line treatments for guttate psoriasis include phototherapy and topical agents. Although systemic antibiotic therapy has been advocated by some authors, the value of such treatment is unclear [<a href="#rid43">43,51</a>]. In addition, data on the efficacy of tonsillectomy, which aims to permanently remove a focus of streptococcal infection, are limited. Patients who progress to chronic plaque psoriasis can be managed according to the treatment approach for this variant. (See <a class="local">'First-line therapies'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H2500863"><span class="h2">First-line therapies</span></p><p class="headingAnchor" id="H2500111"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>Ultraviolet (UV) phototherapy is considered a first-line therapy for guttate psoriasis. This designation is primarily due to its documented efficacy in other forms of psoriasis, its relative safety, and the ability to easily treat large body surface areas. The options for full-body phototherapy for psoriasis include narrowband ultraviolet B (UVB), broadband UVB, and psoralen plus ultraviolet A (PUVA) phototherapy.</p><p>The efficacy of phototherapy for plaque psoriasis is well documented, with narrowband UVB considered the preferred form of phototherapy [<a href="#rid52">52,53</a>]. Narrowband UVB has been more effective than broadband UVB in multiple small, prospective, split-body studies of patients with plaque-type psoriasis [<a href="#rid52">52,54</a>]. Although a randomized trial that compared narrowband UVB with a selective broadband UVB device in 100 patients with plaque-type psoriasis found a difference of efficacy in favor of narrowband UVB that was not statistically significant (56 versus 40 percent of patients achieved disease clearance), the study was underpowered to detect a difference [<a href="#rid55">55</a>]. PUVA was significantly more effective than narrowband UVB in a randomized trial (n = 93). However, the requirement for strict photoprotection following treatment makes PUVA a less favorable choice for therapy [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p>Formal study of the efficacy of phototherapy in guttate psoriasis is limited since most psoriasis studies that have included patients with this variant have failed to stratify treatment results according to the type of psoriasis [<a href="#rid48">48</a>]. A prospective uncontrolled study in which 67 adults with guttate psoriasis were treated with narrowband UVB for guttate psoriasis supports benefit in this population; 52 (78 percent) achieved at least 90 percent improvement in the Psoriasis Area and Severity Index score, and 46 (88 percent) of those patients maintained this response during 18 months of follow-up without treatment [<a href="#rid57">57</a>]. Patients received an average of 20 treatments.</p><p>Potential adverse effects of phototherapy include burns, pruritus, and premature skin aging. Increased risks for squamous cell carcinoma and possibly melanoma are associated with long-term PUVA therapy. (See  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Skin cancer'</a>.)</p><p>Patients without access to phototherapy may experience improvement in guttate psoriasis with cautious outdoor sun exposure. The efficacy of this intervention has not been formally evaluated. Based upon clinical experience, 5 to 10 minutes of noontime sun exposure without sunscreen is typically sufficient. Sunburns should be avoided. </p><p class="headingAnchor" id="H2500118"><span class="h3">Topical corticosteroids and vitamin D analogs</span><span class="headingEndMark"> — </span>Multiple randomized trials have supported the efficacy of topical corticosteroids and topical vitamin D analogs for chronic plaque psoriasis [<a href="#rid58">58</a>]. These agents have not been formally evaluated specifically in guttate disease [<a href="#rid48">48</a>].</p><p>A potential impediment to topical treatment of guttate psoriasis is the often widespread nature of the disease, which can make the application of topical agents impractical. Thus, phototherapy is usually preferred for the treatment of patients with numerous lesions. Topical agents may be used as an adjunct to phototherapy. (See <a class="local">'Phototherapy'</a> above.)</p><p>Cutaneous atrophy is a potential adverse effect of topical corticosteroid therapy. To minimize this risk, low-potency agents are typically used on atrophy-prone sites, such as the face and intertriginous areas  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>). Medium- to high-potency agents may be applied to lesions on the trunk or extremities. </p><p>Topical corticosteroids are typically applied to active lesions once to twice daily for around two weeks. Longer courses may be utilized if necessary; however, monitoring for adverse effects is essential. (See  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Corticosteroids'</a> and  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p>Topical vitamin D analogs, such as <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or calcipotriene, may be used alone or in conjunction with topical corticosteroid therapy. Cutaneous irritation is the most common adverse effect of these agents. (See  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Topical vitamin D analogs'</a>.)</p><p class="headingAnchor" id="H2500909"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>In a minority of patients, guttate psoriasis recurs multiple times per year or fails to improve with phototherapy or topical therapies. Although few data are available to support their use, tonsillectomy and systemic therapies used for chronic plaque psoriasis have been utilized in the management of these patients.</p><p class="headingAnchor" id="H2500132"><span class="h3">Tonsillectomy</span><span class="headingEndMark"> — </span>Resolution of recurrent <em>Streptococcus</em>-associated guttate or chronic plaque psoriasis following tonsillectomy has been documented, including in a small randomized trial performed with patients with chronic plaque psoriasis and in case reports and uncontrolled studies [<a href="#rid51">51,59,60</a>]. In one uncontrolled study, five out of six patients with guttate psoriasis that flared with episodes of tonsillitis had complete clearance of the disease after tonsillectomy, and the remaining patient had a lesser degree of improvement [<a href="#rid61">61</a>]. Two of seven patients with chronic plaque psoriasis cleared.</p><p>Based upon the available data, it is conceivable that tonsillectomy may be effective for some patients with recurrent, tonsillitis-associated guttate psoriasis. However, data are insufficient to recommend the routine use of tonsillectomy, and further studies are necessary to evaluate the efficacy of this treatment [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/3419.html" rel="external">"Tonsillectomy in adults: Techniques and perioperative issues"</a> and  <a class="medical medical_review" href="/d/html/6296.html" rel="external">"Tonsillectomy and/or adenoidectomy in children: Indications and contraindications"</a>.)</p><p class="headingAnchor" id="H2502831"><span class="h3">Systemic psoriasis therapies</span><span class="headingEndMark"> — </span>Based upon efficacy demonstrated in chronic plaque psoriasis, treatment with systemic immunomodulatory and immunosuppressive therapies utilized for chronic plaque psoriasis may be attempted in patients with persistent disease that fails to respond to first-line therapies. However, there is a lack of published evidence on the efficacy of these treatments, specifically in guttate psoriasis [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H716080"><span class="h2">Other interventions</span></p><p class="headingAnchor" id="H2501654"><span class="h3">Systemic antibiotics</span><span class="headingEndMark"> — </span>Due to the well-accepted association between streptococcal infection and guttate psoriasis, antibiotic therapy has been proposed as a treatment for this disease. Overall, data remain insufficient to support a routine recommendation for antibiotic therapy for skin disease in guttate psoriasis [<a href="#rid51">51,62</a>]. However, patients with active streptococcal infection (eg, streptococcal pharyngitis or perianal streptococcal infection) should be treated with antibiotic therapy to resolve these infections, as indicated. (See <a class="local">'Streptococcal infection'</a> above and  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a>.)</p><p>Evidence in support of antistreptococcal antibiotics is limited to a few uncontrolled studies that document improvement in guttate or plaque-type psoriasis after treatment with macrolides or treatment with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> given with or without other antistreptococcal agents [<a href="#rid63">63-66</a>]. The few randomized trials performed are of low quality and have not yielded favorable results [<a href="#rid51">51</a>]. In a randomized trial in 20 patients with psoriasis (19 with guttate psoriasis) that compared 14 days of treatment with <a class="drug drug_general" data-topicid="9751" href="/d/drug information/9751.html" rel="external">penicillin V</a> or <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> (both 250 mg four times daily) plus rifampin (300 mg twice daily) during the final five days of therapy with a 14-day treatment regimen consisting of penicillin or erythromycin monotherapy, neither treatment approach reduced disease severity [<a href="#rid67">67</a>]. </p><p>A potential role for <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> therapy resurfaced in a subsequent prospective uncontrolled study of 52 patients with guttate psoriasis. Monotherapy with rifampin (600 mg per day) for 60 days was associated with reductions of psoriasis severity scores regardless of the presence or absence of evidence of recent streptococcal infection. Based upon this finding, the authors postulated that immunomodulatory effects of rifampin may have contributed to the observed effect [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H350234063"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112498.html" rel="external">"Society guideline links: Psoriasis"</a>.)</p><p class="headingAnchor" id="H2503181"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Guttate psoriasis is a variant of psoriasis that is characterized by the presence of small, erythematous papules and plaques on the skin. Guttate psoriasis is most frequently diagnosed in adolescents and young adults but may occur in other age groups. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Genetic and environmental factors likely contribute to the development of guttate psoriasis. The HLA-Cw*0602 allele has been strongly linked to this disorder, and streptococcal infection often precedes its development. The latency period between streptococcal infection and the appearance of skin lesions is typically two to three weeks. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The relationship between streptococcal infection and guttate psoriasis is not fully understood. Cross-reactivity between streptococcal and epidermal antigens, stimulatory effects of streptococcal superantigens, and/or the induction of an innate immune response by streptococcal components may be involved. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The skin lesions of guttate psoriasis are typically 2 to 15 mm in diameter with overlying, fine scale  (<a class="graphic graphic_picture graphicRef55141 graphicRef64836" href="/d/graphic/55141.html" rel="external">picture 1A-B</a>). The trunk and proximal extremities are the principle sites of involvement. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of guttate psoriasis can usually be made by clinical examination. In difficult cases, a skin biopsy may be used to support the diagnosis and rule out other conditions. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course </strong>– Guttate psoriasis may spontaneously remit over the course of several weeks to months or may persist and progress to chronic plaque disease. The course of the disease is unpredictable. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment </strong>– For patients with widespread lesions of guttate psoriasis who desire treatment, we suggest treatment with narrowband ultraviolet B (UVB) phototherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Topical corticosteroids, topical vitamin D analogs, and other forms of phototherapy are alternative treatments. (See <a class="local">'First-line therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other therapies </strong>– Treatment with the systemic immunomodulatory and immunosuppressive agents utilized for plaque psoriasis may be attempted in patients with guttate psoriasis that fails to improve with phototherapy and topical therapies. The efficacy of such treatment in guttate psoriasis has not been well studied. (See <a class="local">'Systemic psoriasis therapies'</a> above.)</p><p></p><p class="bulletIndent2">The use of tonsillectomy and systemic antibiotic therapy for the treatment of the skin manifestations of guttate psoriasis is controversial. Further study is necessary to explore the efficacy of these interventions. These interventions are not recommended for routine treatment of guttate psoriasis. Active streptococcal infection should be treated with antibiotics, as indicated. (See <a class="local">'Tonsillectomy'</a> above and <a class="local">'Systemic antibiotics'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3:121.</a></li><li><a class="nounderline abstract_t">Rigopoulos D, Gregoriou S, Katrinaki A, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate. Eur J Dermatol 2010; 20:189.</a></li><li><a class="nounderline abstract_t">Kundakci N, Türsen U, Babiker MO, Gürgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41:220.</a></li><li><a class="nounderline abstract_t">Valenzuela F, Silva P, Valdés MP, Papp K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr 2011; 102:810.</a></li><li><a class="nounderline abstract_t">Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007; 87:335.</a></li><li><a class="nounderline abstract_t">Kwon HH, Na SJ, Jo SJ, Youn JI. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol 2012; 39:260.</a></li><li><a class="nounderline abstract_t">Ko HC, Jwa SW, Song M, et al. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol 2010; 37:894.</a></li><li><a class="nounderline abstract_t">Ferrándiz C, Pujol RM, García-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46:867.</a></li><li><a class="nounderline abstract_t">Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol 2012; 51:53.</a></li><li><a class="nounderline abstract_t">Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 1997; 109:183.</a></li><li><a class="nounderline abstract_t">Wu D, Wu Y, Liu JL, et al. Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis. Genet Mol Res 2011; 10:3109.</a></li><li><a class="nounderline abstract_t">Holm SJ, Sakuraba K, Mallbris L, et al. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol 2005; 125:721.</a></li><li><a class="nounderline abstract_t">Mallbris L, Wolk K, Sánchez F, Ståhle M. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study. BMC Dermatol 2009; 9:5.</a></li><li><a class="nounderline abstract_t">Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126:740.</a></li><li><a class="nounderline abstract_t">Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol 2000; 143:1177.</a></li><li><a class="nounderline abstract_t">Gudjónsson JE, Kárason A, Antonsdóttir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118:362.</a></li><li><a class="nounderline abstract_t">NORRLIND R. Psoriasis following infections with hemolytic streptococci. Acta Derm Venereol 1950; 30:64.</a></li><li><a class="nounderline abstract_t">Prinz JC. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26:326.</a></li><li><a class="nounderline abstract_t">Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128:39.</a></li><li><a class="nounderline abstract_t">Mallbris L, Larsson P, Bergqvist S, et al. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005; 124:499.</a></li><li><a class="nounderline abstract_t">Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol 2013; 30:424.</a></li><li><a class="nounderline abstract_t">Patrizi A, Costa AM, Fiorillo L, Neri I. Perianal streptococcal dermatitis associated with guttate psoriasis and/or balanoposthitis: a study of five cases. Pediatr Dermatol 1994; 11:168.</a></li><li><a class="nounderline abstract_t">Herbst RA, Hoch O, Kapp A, Weiss J. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol 2000; 42:885.</a></li><li><a class="nounderline abstract_t">Veraldi S, Lunardon L, Dassoni F. Guttate psoriasis triggered by chickenpox. G Ital Dermatol Venereol 2009; 144:501.</a></li><li><a class="nounderline abstract_t">Ito T, Furukawa F. Psoriasis guttate acuta triggered by varicella zoster virus infection. Eur J Dermatol 2000; 10:226.</a></li><li><a class="nounderline abstract_t">Elewski B. Does pityrosporum ovale have a role in psoriasis? Arch Dermatol 1990; 126:1111.</a></li><li><a class="nounderline abstract_t">Sandhu K, Jain R, Kaur I, Kumar B. Role of Pityrosporum ovale in guttate psoriasis. J Dermatol 2003; 30:252.</a></li><li><a class="nounderline abstract_t">Ali E, Mohamed A, Abuodeh J, et al. SARS-CoV-2 and guttate psoriasis: A case report and review of literature. Clin Case Rep 2021; 9:e04568.</a></li><li><a class="nounderline abstract_t">Song WJ, Lim Y, Jo SJ. De novo guttate psoriasis following coronavirus disease 2019 vaccination. J Dermatol 2022; 49:e30.</a></li><li><a class="nounderline abstract_t">Lehmann M, Schorno P, Hunger RE, et al. New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol 2021; 35:e752.</a></li><li><a class="nounderline abstract_t">Janodia RP, Kupetsky EA. Guttate Psoriasis Following COVID-19 Infection. Cutis 2022; 109:101.</a></li><li><a class="nounderline abstract_t">Horner KL, Chien AJ, Edenholm M, Hornung RL. Winnie the Pooh and psoriasis too: an isomorphic response of guttate psoriasis in a tattoo. Pediatr Dermatol 2007; 24:E70.</a></li><li><a class="nounderline abstract_t">Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012; 6:518.</a></li><li><a class="nounderline abstract_t">Brigant F, Clavel G, Chatelain D, et al. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J 2011; 17:11.</a></li><li><a class="nounderline abstract_t">Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40:233.</a></li><li><a class="nounderline abstract_t">Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol 2010; 32:568.</a></li><li><a class="nounderline abstract_t">Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, et al. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis 2008; 14:1462.</a></li><li><a class="nounderline abstract_t">Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, et al. Psoriasis--as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009; 30:494.</a></li><li><a class="nounderline abstract_t">Diluvio L, Vollmer S, Besgen P, et al. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006; 176:7104.</a></li><li><a class="nounderline abstract_t">Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004; 138:83.</a></li><li><a class="nounderline abstract_t">Ruiz-Romeu E, Ferran M, Sagristà M, et al. Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis. J Allergy Clin Immunol 2016; 138:491.</a></li><li><a class="nounderline abstract_t">Christophers E, Kiene P. Guttate and plaque psoriasis. Dermatol Clin 1995; 13:751.</a></li><li><a class="nounderline abstract_t">Krishnamurthy K, Walker A, Gropper CA, Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol 2010; 9:241.</a></li><li><a class="nounderline abstract_t">Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 1996; 132:717.</a></li><li><a class="nounderline abstract_t">Williams RC, McKenzie AW, Roger JH, Joysey VC. HL-A antigens in patients with guttate psoriasis. Br J Dermatol 1976; 95:163.</a></li><li><a class="nounderline abstract_t">Svedbom A, Mallbris L, Larsson P, et al. Long-term Outcomes and Prognosis in New-Onset Psoriasis. JAMA Dermatol 2021; 157:1.</a></li><li><a class="nounderline abstract_t">Pfingstler LF, Maroon M, Mowad C. Guttate psoriasis outcomes. Cutis 2016; 97:140.</a></li><li><a class="nounderline abstract_t">Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. Br J Dermatol 2001; 145:891.</a></li><li><a class="nounderline abstract_t">Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000; :CD001213.</a></li><li><a class="nounderline abstract_t">Maruani A, Samimi M, Stembridge N, et al. Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. Cochrane Database Syst Rev 2019; 4:CD011541.</a></li><li><a class="nounderline abstract_t">Dupire G, Droitcourt C, Hughes C, Le Cleach L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2019; 3:CD011571.</a></li><li><a class="nounderline abstract_t">Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.</a></li><li><a class="nounderline abstract_t">Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011; 64:936.</a></li><li><a class="nounderline abstract_t">Walters IB, Burack LH, Coven TR, et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40:893.</a></li><li><a class="nounderline abstract_t">Kirke SM, Lowder S, Lloyd JJ, et al. A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol 2007; 127:1641.</a></li><li><a class="nounderline abstract_t">Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006; 142:836.</a></li><li><a class="nounderline abstract_t">Fernández-Guarino M, Aboín-González S, Velázquez D, et al. Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: Results and Patient Assessment. Dermatology 2016; 232:626.</a></li><li><a class="nounderline abstract_t">Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; :CD005028.</a></li><li><a class="nounderline abstract_t">Wilson JK, Al-Suwaidan SN, Krowchuk D, Feldman SR. Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol 2003; 20:11.</a></li><li><a class="nounderline abstract_t">Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: a systematic review. J Am Acad Dermatol 2015; 72:261.</a></li><li><a class="nounderline abstract_t">Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol Allied Sci 1996; 21:546.</a></li><li><a class="nounderline abstract_t">Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol 2001; 145:886.</a></li><li><a class="nounderline abstract_t">Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. J Am Acad Dermatol 1986; 14:761.</a></li><li><a class="nounderline abstract_t">Polat M, Lenk N, Yalcin B, et al. Efficacy of erythromycin for psoriasis vulgaris. Clin Exp Dermatol 2007; 32:295.</a></li><li><a class="nounderline abstract_t">Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 2000; 27:508.</a></li><li><a class="nounderline abstract_t">Tsankov N, Grozdev I. Rifampicin in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2009; 23:93.</a></li><li><a class="nounderline abstract_t">Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992; 26:458.</a></li></ol></div><div id="topicVersionRevision">Topic 15280 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180464" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20123642" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12031031" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664589" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology and quality of life of patients with psoriasis in Chile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598037" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22211370" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20860740" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical course of guttate psoriasis: long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063483" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Psoriasis of early and late onset: a clinical and epidemiologic study from Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22182378" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242505" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22194166" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16185272" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Distinct HLA-C/KIR genotype profile associates with guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480679" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439971" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122018" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : HLA-C and guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841557" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15409831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Psoriasis following infections with hemolytic streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422184" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739285" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The role of streptococcal infection in the initiation of guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737189" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360462" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041660" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Perianal streptococcal dermatitis associated with guttate psoriasis and/or balanoposthitis: a study of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767696" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755956" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guttate psoriasis triggered by chickenpox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10725825" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Psoriasis guttate acuta triggered by varicella zoster virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2383044" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Does pityrosporum ovale have a role in psoriasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692367" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Role of Pityrosporum ovale in guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34295501" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : SARS-CoV-2 and guttate psoriasis: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34713443" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : De novo guttate psoriasis following coronavirus disease 2019 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34309932" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35659815" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Guttate Psoriasis Following COVID-19 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958785" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Winnie the Pooh and psoriasis too: an isomorphic response of guttate psoriasis in a tattoo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398059" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21696691" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580412" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20520526" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-αinhibitor therapy. A study of 16 biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18383177" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Guttate psoriasis induced by infliximab in a child with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781993" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Psoriasis--as an autoimmune disease caused by molecular mimicry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709873" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15373909" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056267" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8785880" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Guttate and plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20232586" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651734" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/952752" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : HL-A antigens in patients with guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33851956" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term Outcomes and Prognosis in New-Onset Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919501" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Guttate psoriasis outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11899141" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A systematic review of treatments for guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796758" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Interventions for guttate psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30958563" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30835819" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antistreptococcal interventions for guttate and chronic plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811850" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21429620" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A review of phototherapy protocols for psoriasis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10365919" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380117" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847198" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27883996" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: Results and Patient Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370616" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Topical treatments for chronic plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12558839" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455609" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of tonsillectomy on psoriasis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118579" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clearance of recalcitrant psoriasis after tonsillectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11899140" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3086388" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397353" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of erythromycin for psoriasis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10989574" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : An open trial of oral macrolide treatment for psoriasis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18384550" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rifampicin in the treatment of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1564153" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
